26 Apr 2026
The Wegovy Pill in Ireland: When Will It Be Available and What Do We Know So Far?
All medical information is reviewed by our clinical partners at MedicOnline.
Dr. Jahan Khan, CMO @ MedicOnline
IMC 409788
A daily pill that delivers the same weight loss as a weekly injection - no needles, no fuss. It sounds too good to be true, but the Wegovy pill is already a reality in the United States. So when will it reach Ireland? Here's everything you need to know right now.
If you've been following the world of weight management, you'll know that GLP-1 medications have genuinely transformed how we think about obesity treatment. Injectable Wegovy (semaglutide 2.4mg) became available in Ireland in March 2025 - a landmark moment for Irish patients. But the next chapter is already being written, and it comes in tablet form.
At Bua Health, we're closely monitoring developments in oral semaglutide so we can keep our patients informed and prepared. This post pulls together everything that's currently known about the Wegovy pill - the science, the regulatory timeline, the realistic availability window for Ireland, and what you should be doing in the meantime.
What Exactly Is the Wegovy Pill?
The Wegovy pill is an oral tablet form of semaglutide - the same active ingredient already available in the weekly Wegovy injection. Manufactured by Novo Nordisk, it contains 25mg of semaglutide and is taken once daily. Like the injection, it works as a GLP-1 receptor agonist, mimicking a natural gut hormone to reduce appetite, slow digestion, and help you feel fuller for longer.
It's important to distinguish this from Rybelsus, which is an oral semaglutide tablet already available in Ireland - but Rybelsus is licensed only for managing type 2 diabetes at doses up to 14mg. The Wegovy pill uses a significantly higher dose (25mg maintenance) specifically developed for weight management.
iIn plain terms: The pill is not a weaker or diluted version of the injection. Clinical trials have shown it delivers comparable results - without a needle.
What Does the Evidence Say?
The Wegovy pill has been rigorously studied through Novo Nordisk's Phase 3 OASIS clinical trial programme, which enrolled approximately 1,300 adults with obesity or overweight with one or more related health conditions. Direct trial link (OASIS 4).
The headline results from the OASIS 4 trial are striking: participants taking oral semaglutide 25mg achieved a mean weight loss of 13.6% at 64 weeks, compared to 2.2% in the placebo group. Among those who fully adhered to treatment, weight loss reached 16.6%. Crucially, approximately one in three participants achieved 20% or greater body weight loss - a result comparable to injectable Wegovy (STEP/OASIS comparator data).
Beyond weight loss, the trial also demonstrated improvements in blood pressure, blood glucose control, and cardiovascular risk markers. For those with prediabetes at baseline, more than 70% saw blood glucose normalise. The safety profile was consistent with what we already know from injectable semaglutide - the most common side effects being gastrointestinal (nausea, constipation, diarrhoea), which typically ease over time.
Frequency
💉 Once weekly subcutaneous injection
💊 Once daily oral tablet
Maintenance dose
💉 2.4mg maintenance dose
💊 25mg maintenance dose
Expected weight loss
💉 ~14.9% average weight loss (STEP trials)
💊 ~13.6-16.6% weight loss (OASIS 4)
Availability in Ireland
💉 Already available in Ireland
💊 Not yet available in Ireland
Administration notes
💉 More predictable absorption
💊 Must be taken fasting (30 min before food)
Where Does the World Stand Right Now?
The United States moved first. The FDA approved the Wegovy pill on 22 December 2025, and Novo Nordisk launched it commercially in the US in early January 2026 - making it the first oral GLP-1 receptor agonist approved specifically for weight management in the world.
For Ireland and the rest of the EU, the pathway is different and moves through the European Medicines Agency (EMA). Novo Nordisk submitted the oral semaglutide 25mg formulation for obesity to the EMA during the second half of 2025, and an EMA committee (CHMP) agenda item in early 2026 indicates active ongoing review.
Ireland connection: In a significant vote of confidence in Irish manufacturing, Novo Nordisk announced a EUR432 million investment to upgrade its Athlone facility specifically to manufacture the oral Wegovy pill for markets outside the US.
The expansion is expected to come online gradually from end 2027 through 2028 - meaning Ireland will play a direct role in supplying this medication to Europe.
The Ireland Timeline For The Wegovy: An Honest Estimate
Here is the regulatory pathway the Wegovy pill must travel before an Irish patient can receive a prescription:
Late 2025
Novo Nordisk submits oral semaglutide 25mg to EMA for approval review.
Early 2026
EMA CHMP committee actively reviewing the submission. Ongoing committee activity confirmed.
Mid-Late 2026 (Expected)
EMA decision anticipated. If approved, centralised marketing authorisation covers all EU member states in principle.
Late 2026 or 2027 (Realistic)
HPRA listing in Ireland, pharmacy stocking, then prescribing to eligible patients.
TBD
HSE reimbursement decision via NCPE review. Private prescription access is likely to come first.
To be clear: as of April 2026, you cannot get the Wegovy pill in Ireland for weight loss. There is no approved tablet version of Wegovy for obesity in Ireland or the EU at this time.
Anyone claiming to sell it here is selling something that is either unlicensed or not what it claims to be - please avoid unregulated online sources.
Who Will Be Eligible For The Wegvy Pill?
Based on the clinical trial criteria and the FDA's approved indications (which are expected to closely mirror the eventual EU approval), the Wegovy pill is designed for adults who meet one of the following thresholds:
- BMI of 30 or above - the standard clinical threshold for obesity where medical intervention is recommended alongside lifestyle changes.
- BMI of 27-29.9 - provided you have at least one weight-related health condition, such as high blood pressure, type 2 diabetes or prediabetes, high cholesterol, or cardiovascular disease.
One practical consideration: the pill must be taken on an empty stomach in the morning with up to 120ml of water, followed by a 30-minute wait before eating, drinking anything else, or taking other oral medications. This is a meaningful daily routine requirement that clinicians will discuss with patients.
Should You Wait for the Pill?
This is the question we hear most often at Bua Health, and the honest answer is: probably not.
Injectable Wegovy is available in Ireland right now. The evidence behind it is extensive, and for patients who are clinically eligible, waiting 12-18 months for a pill when an equally effective treatment exists today is rarely in their best interest - medically or practically.
That said, we understand that needle anxiety is a real barrier for some people. If the injection has been the only thing holding you back from starting treatment, it's absolutely worth staying informed - and worth having a conversation with one of our clinicians about your options in the meantime.
At Bua Health, we offer medically supervised weight management programmes which can include GLP-1 treatments currently available in Ireland. Our clinical partners stay up to date with regulatory developments and will be ready to assess patients for the pill as soon as it becomes available.
Ready to get started with Bua?
With Bua, you're supported by a specialist, doctor-led weight management service from day one. Here's how the process works:
Complete a 2 minute online assessment with your BMI, medical history, medications, and key health details.
Our clinical partners review your submission quickly and invite eligible patients to a remote GP consultation.
Start ongoing support from your care team, including monthly clinical check-ins, unlimited GP support and dietitian guidance.
Frequently Asked Questions
Ready to Start Your Weight Loss Journey Now?
Don't wait for the pill. Effective, medically supervised treatment is available in Ireland today. Our clinical team at Bua Health can help you find the right approach for you.
Related reading: Do I Qualify for Wegovy in Ireland? BMI Criteria, Costs & Eligibility Explained (2026).
Sources & References
- 1. Novo Nordisk (December 2025). Wegovy pill approved in the US as first oral GLP-1 for weight management.
- 2. Bua Health. Wegovy Pill in Ireland - Coming Soon.
- 3. Irish Medical Times (March 2025). Weight loss drug Wegovy now available in Ireland.
- 4. Fierce Pharma (March 2026). Novo plugs $500M into Ireland plant to produce Wegovy pill for markets outside US.
- 5. Applied Clinical Trials (December 2025). FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results.
- 6. Healthwave Ireland (January 2026). Wegovy Weight-Loss Pill: When Could It Be Available in Ireland?
- 7. AJMC (December 2025). FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss.
- 8. IQVIA (January 2026). Outlook for Obesity in 2026: From Consolidation to Acceleration.
Related Blogs
Who Qualifies for Mounjaro in Ireland?
An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.
Read
What weight loss injections are available in Ireland?
A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026
Read
Who can't take Mounjaro? Understanding the contraindications
A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.
ReadWho Qualifies for Mounjaro in Ireland?
An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.
What weight loss injections are available in Ireland?
A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026
Who can't take Mounjaro? Understanding the contraindications
A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.